San Francisco startup Structure Therapeutics can be working on an oral, after-daily GLP-one drug referred to as GSBR-1290—the drug surpassed Wall Street’s expectations in June any time a mid-stage study showed normal weight loss of close to 6% and it options to start out A further mid-stage trial toward the end of this yr—that founder and CEO